Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline

Omnicell has a record of volume growth but volatile profitability and is experiencing poor order visibility. Operating in a competitive market with the healthcare industry under pressure from rising costs, we believe demand for automated pharmacy solutions will fall in priority.

Omnicell: Poor Track Record, Staying On The Sidelines

Atlantica Sustainable Infrastructure

Bally's

Illumina

Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.

These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio

SANTA CLARA, Calif.--( BUSINESS WIRE )--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced that they will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time.

Omnicell to Present at the 41st Annual J.P. Morgan Healthcare Conference

Hecla Mining

MGM Resorts

RadNet

Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.

5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues

SANTA CLARA, Calif.--( BUSINESS WIRE )--Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it will showcase the Company's Advanced Services at this year's American Society of Health-System Pharmacists (ASHP) Midyear 2022 Clinical Meeting and Exhibition, to be held December 5-8, 2022 in Las Vegas.

Omnicell to Showcase Advanced Services Designed to Deliver Enhanced Medication Management Outcomes at ASHP Midyear 2022

SANTA CLARA, Calif.--( BUSINESS WIRE )--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference:

Omnicell to Present at the Piper Sandler 34th Annual Healthcare Conference

Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.

Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut

The healthcare medication management company released lowered guidance.

Why Shares of Omnicell Dropped 33.6% This Week

Omnicell, Inc. (NASDAQ:OMCL ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Dev Weerasuriya - Berenberg Capital Management Joy Zeng - SVB Securities Anne Samuel - JP Morgan David Larsen - BTIG Operator Ladies and gentlemen, thank you for standing-by. My name is [Brent] [ph] and I will be your conference operator today.

Omnicell, Inc. (OMCL) Q3 2022 Earnings Call Transcript

Omnicell (OMCL) delivered earnings and revenue surprises of 6.38% and 4.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q3 Earnings Top Estimates

Omnicell Announces Financial Results for Third Quarter 2022

Omnicell to Release Third Quarter 2022 Financial Results on November 2, 2022

SANTA CLARA, Calif.--(BUSINESS WIRE)--Omnicell Launches Specialty Pharmacy Services to Support Outpatient Medication Management and Drive Clinical, Business Outcomes for Health Systems

Omnicell Launches Specialty Pharmacy Services to Support Optimized Outpatient Medication Management and Drive Clinical and Business Outcomes for Health Systems

Allscripts Healthcare Solutions

MDRX vs. OMCL: Which Stock Is the Better Value Option?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Omnicell Highlights Differentiated Strategy and Unique Business Model at 2022 Investor Day

Omnicell Highlights Differentiated Strategy and Unique Business Model at 2022 Investor Day

SANTA CLARA, Calif.--(BUSINESS WIRE)--Omnicell to Present at the 2022 Wells Fargo Healthcare Conference

Omnicell to Present at the 2022 Wells Fargo Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Omnicell to Host Investor Day on September 20, 2022

Omnicell to Host Investor Day on September 20, 2022

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?

Omnicell, Inc. (NASDAQ:OMCL ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Joy Zeng - SVB Securities Stan Berenshteyn - Wells Fargo Jessica Tassan - Piper Sandler Lucas Baranowski - Craig Hallum Dev Weerasuriya - Berenberg Capital Markets Operator Good day, everyone. And welcome to Omnicell Q2 2022 Financial Results Conference Call.

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2022 Results - Earnings Call Transcript

Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates

SANTA CLARA, Calif.--(BUSINESS WIRE)--Omnicell Announces Financial Results for Second Quarter 2022

News for Omnicell Stock (OMCL)